Pfizer Stock Forecast for 2022 - 2025 - 2030

Updated on 05/25/2022

Stock Rating
7 / 10
Price Target
$55.00
Consensus
Outperform
Upside
2.98%
Analysts
16
Stock Rating
7
Upside
2.98%
Analysts
16
Price Target
$55.00

The average target price for Pfizer's stock set by sixteen renowned analysts in recent months is $55.00, representing a potential upside of approximately 2.98% from its last closing price if met by 2023. This estimation is based on a high estimate of $75.00 and a low estimate of $48.00. If you are looking to invest in the stock, it's important to research and compare different companies.

$55.00

2.98% Upside

Outperform
Outperform

Pfizer Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Fair Value has grown by 47.33%, from $41.58 to $61.26. For the next year, analysts are expecting Fair Value to reach an impressive $98.96 – an increase of 61.54%. By 2030, professionals predict that Pfizer's Fair Value will decrease by 26.7%, to a mere $44.91.

2022 Fair Value Forecast
$98.96
2023 Fair Value Forecast
$75.68
2024 Fair Value Forecast
$62.51
2025 Fair Value Forecast
$60.15
2026 Fair Value Forecast
$58.49
2027 Fair Value Forecast
$58.91
2028 Fair Value Forecast
$48.37
2029 Fair Value Forecast
$44.91
2030 Fair Value Forecast
$44.91
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ABBV Stock Forecast AbbVie Outperform 6
$149.11 $152.52 12.5% 19
AZN Stock Forecast AstraZeneca PLC Outperform 3
£104.94 £136.08 39% 13
ABT Stock Forecast Abbott Laboratories Outperform 7
$113.77 $141.24 23.06% 19
COST Stock Forecast Costco Wholesale Outperform 6
$437.71 $584.00 34.11% 12
BMY Stock Forecast Bristol-Myers Squibb Outperform 8
$77.13 $76.69 1.13% 16

Pfizer Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Revenue has grown by 99.11%, from $40.83B to $81.29B. For the next year, analysts are expecting Revenue to reach a reasonable $105.90B – an increase of 30.28%. By 2030, professionals predict that Pfizer's Revenue will decrease by 34.71%, to a mere $53.07B.

2022 Rev Forecast
$105.90B
2023 Rev Forecast
$79.92B
2024 Rev Forecast
$69.26B
2025 Rev Forecast
$67.30B
2026 Rev Forecast
$65.06B
2027 Rev Forecast
$64.48B
2028 Rev Forecast
$55.63B
2029 Rev Forecast
$53.31B
2030 Rev Forecast
$53.07B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
AMGN Stock Forecast Amgen Hold 6
$251.89 $246.46 -0.75% 13
CSL Stock Forecast CSL Outperform 4
$266.28 $228.01 -14.01% 10
MMM Stock Forecast 3M Hold 5
$145.75 $188.41 9.98% 17

Pfizer Dividend per Share Forecast for 2022 - 2025 - 2030

In the past three years, Pfizer's DPS has seen a tremendous increase, going from $1.36 to $1.56 – an increase of 14.71%. Next year, analysts are expecting DPS to reach $1.62 – an increase of 3.85%. Over the next nine years, the forecast is for DPS to grow by 8.33%.

2022 DPS Forecast
$1.62
2023 DPS Forecast
$1.68
2024 DPS Forecast
$1.72
2025 DPS Forecast
$1.77
2026 DPS Forecast
$1.72
2027 DPS Forecast
$1.67
2028 DPS Forecast
$1.67
2029 DPS Forecast
$1.67
2030 DPS Forecast
$1.69
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 5
$257.45 $270.20 10.7% 3
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14
CL Stock Forecast Colgate-Palmolive Hold 5
$78.12 $84.90 4.97% 9

Pfizer Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Free Cash Flow has grown by 115.77%, rising from $13.84B to $29.87B. For next year, analysts predict earnings per share of $34.79B, which would mean an increase of 16.47%. In 2030, professionals predict that Pfizer's Free Cash Flow will decrease by 49.08%, reaching $15.21B.

2022 FCF Forecast
$34.79B
2023 FCF Forecast
$30.67B
2024 FCF Forecast
$24.18B
2025 FCF Forecast
$23.37B
2026 FCF Forecast
$22.93B
2027 FCF Forecast
$21.67B
2028 FCF Forecast
$16.77B
2029 FCF Forecast
$15.65B
2030 FCF Forecast
$15.21B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4519 Stock Forecast Chugai Pharmaceutical Hold 3
¥3.79k ¥0.00 18.73% 0
BAS Stock Forecast BASF Outperform 5
48.76€ 78.27€ 31.26% 16
BNTX Stock Forecast BioNTech Hold 0
$284.21 $0.00 -11.75% 3

Pfizer Net Income Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Net Income has grown by 97.07%, rising from $11.15B to $21.98B. For next year, analysts predict earnings per share of $40.98B, which would mean an increase of 86.43%. According to professionals, by 2030, Pfizer's Net Income will have decreased by 14.38%, falling all the way down to $18.82B.

2022 NI Forecast
$40.98B
2023 NI Forecast
$31.82B
2024 NI Forecast
$25.70B
2025 NI Forecast
$24.66B
2026 NI Forecast
$23.88B
2027 NI Forecast
$23.83B
2028 NI Forecast
$20.02B
2029 NI Forecast
$18.84B
2030 NI Forecast
$18.82B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 2
¥2.83k ¥0.00 36.07% 0
ALC Stock Forecast Alcon Outperform 0
CHF79.00 CHF0.00 15.3% 14
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3

Pfizer EBITDA Forecast for 2022 - 2025 - 2030

In the past three years, Pfizer's EBITDA has seen significant growth, rising from $13.47B to $31.95B – a growth of 137.24%. In the next year, analysts believe that EBITDA will reach an impressive $48.44B – an increase of 51.62%. By 2030, professionals believe that Pfizer's EBITDA will have decreased by an astonishing 39.14%, plummeting to just $19.44B.

2022 EBITDA Forecast
$48.44B
2023 EBITDA Forecast
$37.31B
2024 EBITDA Forecast
$31.16B
2025 EBITDA Forecast
$29.88B
2026 EBITDA Forecast
$29.39B
2027 EBITDA Forecast
$29.07B
2028 EBITDA Forecast
$22.41B
2029 EBITDA Forecast
$19.65B
2030 EBITDA Forecast
$19.44B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
A Stock Forecast Agilent Technologies Outperform 7
$124.41 $172.40 28.61% 2
BN Stock Forecast Danone Hold 4
54.87€ 62.59€ 2.06% 18
BIIB Stock Forecast Biogen Outperform 4
$202.54 $287.21 12.32% 24

Pfizer EBIT Forecast for 2022 - 2025 - 2030

Pfizer's EBIT has seen astonishing growth in the last three years, rising from $7.36B to $26.85B – a growth of 264.99%. In the next year, analysts believe that EBIT will reach an impressive $44.31B – an increase of 65.07%.

2022 EBIT Forecast
$44.31B
2023 EBIT Forecast
$33.76B
2024 EBIT Forecast
$27.33B
2025 EBIT Forecast
$27.59B
2026 EBIT Forecast
$26.95B
2027 EBIT Forecast
$27.08B
2028 EBIT Forecast
$22.66B
2029 EBIT Forecast
$21.42B
2030 EBIT Forecast
$21.52B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4503 Stock Forecast Astellas Pharma Outperform 2
¥1.80k ¥0.00 33.33% 0
CHD Stock Forecast Church & Dwight Hold 5
$90.43 $88.52 9.48% 9
ERF Stock Forecast Eurofins Scientific Hold 2
86.95€ 0.00€ 20.76% 10

Pfizer EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's EPS has grown by 47.33%, from $3.00 to $4.42. For the next year, analysts are expecting EPS to reach an impressive $7.14 – an increase of 61.54%. By 2030, professionals predict that Pfizer's EPS will decrease by 26.7%, to a mere $3.24.

2022 EPS Forecast
$7.14
2023 EPS Forecast
$5.46
2024 EPS Forecast
$4.51
2025 EPS Forecast
$4.34
2026 EPS Forecast
$4.22
2027 EPS Forecast
$4.25
2028 EPS Forecast
$3.49
2029 EPS Forecast
$3.24
2030 EPS Forecast
$3.24
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 0
$127.05 $209.00 60.96% 10
4523 Stock Forecast Eisai Hold 0
¥6.85k ¥0.00 -3.61% 0
CRDA Stock Forecast Croda International Plc Outperform 3
£67.30 £85.37 29.27% 13

© Copyright 2022 | Stock Forecast | All Rights Reserved